Pulmatrix, Inc. Logo

Pulmatrix, Inc.

Develops inhaled therapies for respiratory and CNS disorders using its iSPERSE™ technology.

PULM | US

Overview

Corporate Details

ISIN(s):
US74584P3010
LEI:
Country:
United States of America
Address:
945 CONCORD STREET, 1701 FRAMINGHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel inhaled therapeutic products. The company leverages its proprietary iSPERSE™ technology platform to create innovative, pulmonary-delivered treatments for patients with serious diseases. Its product pipeline is focused on addressing serious respiratory and pulmonary diseases, as well as central nervous system (CNS) disorders. Pulmatrix aims to pioneer patient care and provide transformational medicines through its advanced inhalation technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Pulmatrix, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pulmatrix, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pulmatrix, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea 206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America EPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.